New study checks how liver issues affect cancer drug pelabresib

NCT ID NCT07422610

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 09, 2026 · Updated 3 times

Summary

This early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This research aims to find the right dose for patients with liver impairment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pelabresib
What this could lead to: If successful, this study could help doctors determine the right dose of pelabresib for patients with liver problems, potentially making treatment safer and more effective.
What could go wrong: This is a very early, small study (24 people) focused on drug levels, not on curing cancer. It may not lead to any new treatments, and liver impairment could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES AND HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer follicular lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES AND HEPATIC IMPAIRMENT

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

Bordeaux, 33075, France
Novartis Investigative Site
RECRUITING

Saint-Herblain, 44805, France
Novartis Investigative Site
RECRUITING

Candiolo, TO, 10060, Italy
Novartis Investigative Site
RECRUITING

Pozuelo de Alarcón, Madrid, 28223, Spain
Novartis Investigative Site
RECRUITING

Barcelona, 08023, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28040, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28050, Spain
Novartis Investigative Site
RECRUITING

London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.